Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO

Neurology: Neuroimmunology and NeuroInflammation

Volumn 1, Issue 3, 2014, Pages

  Gelfand, Jeffrey M ^a   Cotter, Jennifer ^b   Klingman, Jeffrey ^c   Huang, Eric J ^b   Cree, Bruce A C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AQUAPORIN 4; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G ANTIBODY; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; ASTROCYTOSIS; AUTOPSY; BRAIN CORTEX; BRAIN DAMAGE; BRAIN STEM; CASE REPORT; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CLOSTRIDIUM DIFFICILE INFECTION; DEEP VEIN THROMBOSIS; DEMYELINATING DISEASE; DISEASE COURSE; DRUG PULSE THERAPY; ENTERIC FEEDING; EXPANDED DISABILITY STATUS SCALE; HERPES ZOSTER OPHTHALMICUS; HICCUP; HUMAN; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MACROPHAGE; MALE; MIDDLE AGED; MONOCYTE; MYELITIS; MYELOOPTIC NEUROPATHY; NAUSEA; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA EXCHANGE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; SPINAL CORD LESION; SUBCORTEX; TREATMENT DURATION; URINARY TRACT INFECTION; UROSEPSIS; VISUAL IMPAIRMENT; VOMITING; WEIGHT REDUCTION;

EID: 84948185953     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000034     Document Type: Article

References (11)

1. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68:603-605.
2. Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 2008;8:427-433.
3. Lowenstein H, Shah A, Chant A, Khan A. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. Transpl Int 2006;19:927-936.
4. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260-270.
5. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-1839.
6. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:1819-1828.
7. Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol 2013;4: 1000152.
8. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108.
9. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001;50:646-657.
10. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-2712.
11. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117:759-765.